Testosterone Lawsuit News: Bernstein Liebhard LLP Notes FDA Approval of New Testosterone Therapy Medication
NEW YORK, March 7, 2014 /PRNewswire/ -- As testosterone lawsuits (http://www.testosteronelawsuitcenter.com/ ) continue to mount in courts around the country, Bernstein Liebhard LLP notes that the U.S. Food & Drug Administration (FDA) has granted approval to Aveed, a testosterone medication developed by Endo Pharmaceuticals. The FDA's approval of Aveed comes just weeks after the agency announced it would conduct a safety review of prescription low testosterone therapies after some studies indicated these drugs might raise the risk of heart attacks, strokes and other cardiovascular events in certain men.
"Since the FDA announced its review, a number of testosterone treatment lawsuits have already been filed on behalf of men who allegedly suffered heart attacks, strokes, and dangerous blood clots due to testosterone therapy," says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free and confidential case reviews to individuals who may have suffered heart attacks, strokes, deep vein thrombosis or pulmonary embolism due to their use of testosterone treatment therapies.
Testosterone Treatment Lawsuits
Prescription testosterone therapies are approved to treat low testosterone in men who suffer from the condition due to an underlying medical issue. Other medications in this class include:
- Axiron
- AndroDerm
- AndroGel
- Bio-T Gel
- Delatestryl
- Depo-Testosterone
- Foresta
- Striant
- Testopel
- Testim
On January 31, 2014, the FDA announced that it was reviewing the heart risks that may be associated with prescription testosterone therapies after two studies found a high rate of serious cardiovascular events in men with preexisting heart problems who received testosterone. The FDA has not yet concluded that these drugs will raise the risk of such heart events, but has advised doctors to weigh their risk and benefits when they are prescribed.
On February 24, 2014, the consumer group Public Citizen petitioned the FDA to add strong warnings to the labels of all prescription testosterone therapies to warn of their potential heart risks. Public Citizen also had urged the FDA to delay its approval of Aveed.
Men who may have suffered strokes, heart attacks, deep vein thrombosis, pulmonary embolism or another serious cardiovascular event after taking AndroGel or another one of the above prescription testosterone treatment therapies may be eligible to file a lawsuit seeking compensation from its manufacturer. Learn more about filing a testosterone treatment lawsuit by calling our Firm today at (888) 340-4807.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(888) 340-4807
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.testosteronelawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author
Logo - http://photos.prnewswire.com/prnh/20120202/MM47134LOGO
SOURCE Bernstein Liebhard LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article